Aspen Pharmacare CEO Stephen Saad talks to Business Day TV about its preliminary agreement with Johnson & Johnson
03 November 2020 - 07:29
byBusiness Day TV
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Aspen Pharmacare has reached a preliminary agreement with Johnson & Johnson to manufacture the US company’s Covid-19 vaccine should its clinical trials prove successful. The production will be done at Aspen’s Port Elizabeth facility.
Business Day TV spoke to CEO Stephen Saad for more detail on the agreement.
Aspen Pharmacare CEO Stephen Saad talks to Business Day TV about the preliminary agreement with Johnson & Johnson to manufacture the US company's Covid-19 vaccine
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
News Leader
WATCH: How Aspen secured a Covid-19 vaccine deal
Aspen Pharmacare CEO Stephen Saad talks to Business Day TV about its preliminary agreement with Johnson & Johnson
Aspen Pharmacare has reached a preliminary agreement with Johnson & Johnson to manufacture the US company’s Covid-19 vaccine should its clinical trials prove successful. The production will be done at Aspen’s Port Elizabeth facility.
Business Day TV spoke to CEO Stephen Saad for more detail on the agreement.
Aspen Pharmacare CEO Stephen Saad talks to Business Day TV about the preliminary agreement with Johnson & Johnson to manufacture the US company's Covid-19 vaccine
Aspen bags Covid-19 vaccine deal with Johnson & Johnson
MARKET WRAP: Aspen boosts JSE gains with biggest rise in 20 years on vaccination deal
WATCH: Stock picks — Pepkor and Aspen
Despite Covid-19, top-end Aspen real estate is selling at a pace
Aspen: over the worst
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.